INTRODUCTION
STUDY GOAL AND OBJECTIVES
The objectives of the study are to present a comprehensive look at disorders that affect the mind. An
overall discussion of mental health is presented along with an in-depth discovery of the various diseases and disorders that present significant
problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders.
REASONS
FOR DOING THIS STUDY
This BBC study is presented to highlight the exciting area of mental health. Because in-depth study of the workings of
the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has
provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study
analyzes the current psychotherapeutics and explores the new psychotherapeutics that are in the pipeline to treat mental disorders. The study also
addresses the many and varied issues and trends affecting the market. Manufacturers have increased the pace of research and development for
psychotherapeutic products fueled by demand for new and better compounds to treat psychological disorders. Because of the rapidly evolving climate of
psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of psychotherapeutics must remain ever vigilant of
the changing environment and strive to keep abreast of current and potential opportunities.
SCOPE OF STUDY
The report is designed
to be a comprehensive business tool to provide an in-depth look at the fascinating world of mental health. The geographic scope of the report is
global with an emphasis on the United States. The report identifies the different disorders in mental health; gives an explanation of the disorders;
cites incidence; identifies specific drug types; presents current treatments, market size and market participants; and presents potential treatments
in research and development. The report describes the industry in detail, its relationship to the healthcare industry and healthcare reform, its
participants, and its trends for the future. Within the Market for Prescription Psychotherapeutic Drugs, the following markets are evaluated:
- Prescription Central Nervous System Depressants and Antianxiety Drugs
- Prescription Central Nervous System Antidepressant Drugs
- Prescription Central Nervous System Antimanic Drugs
- Prescription Central Nervous System Antipsychotic Drugs
- Prescription Central Nervous System Stimulant Drugs
- Prescription Central Nervous System Cholinesterase Inhibitor and Miscellaneous Alzheimer Treatment Drugs
- Prescription Central Nervous System Substance Abuse Treatment Drugs
All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size,
identifying current and potential market drivers, forecasting for 2002 and 2007, assessing current and potential competitors and identifying current
competitor market shares.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based
on extensive first-hand interviews with primary executives, product managers, clinical specialists and doctors involved in mental health and
psychotherapeutics. Industry experts' perspectives as well as company reports were used in the market analysis. Background information was obtained
from various government, business, medical journal and trade magazines. Key information from published literature was used to conduct interviews with
over 85 industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and /or adjust
market size and market share estimates, as well as formulating market projections.
View Cart
